Kindred BioSciences (Nasdaq: KIN) Hits Yearly High on Heavy Volume

Kindred BioSciences Inc. – Nasdaq: KIN

Kindred BioSciences Inc. is a biotechnology firm that leverages the R&D funding of human pharmaceuticals by re-purposing existing human drugs for the pet market. Traded on the Nasdaq under ticker KIN, the shares are trading, on heavy volume, today at their highest point in over a year – $6.30.

Based in Burlingame, CA, Kindred Bioscience’s stated mission is to bring pets the same kind of innovative, breakthrough medicines that humans have access to. Kindred Bioscience is one of the first pet biotechs in the world, and has a world-class team, including the former Director of FDA’s Center for Veterinary Medicine and the former Head of Biotherapeutics Clinical Research at Genentech. They hope to arbitrage the differences in the market size for human pharmaceuticals (about 10 times larger than for pets) and the expense for developing those pharmaceuticals (about 100 times less).

Kindred Biosciences has no reported sales and KIN has never experienced positive EPS. However, KIN is rated as a “Strong Buy” by the only two analysts that cover the shares.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/13/2017
Ticker Symbol KIN
Last Price a/o 12:27 PM EST  $                      6.23
Average Volume 82,000
Market Cap $113.5 million
Sales
Shares Outstanding 19.74 million
Share Float 17.17 million
Shortable Yes
Optionable Yes
Inside Ownership 15.97%
Short Float 0.23%
Short Interest Ratio 0.48
Quarterly Return 10.58%
YTD Return 35.29%
Year Return 74.77%

Magellan Petroleum Corporation (Nasdaq: MPET) Up Despite Lawsuit Threat

Magellan Petroleum Corporation – Nasdaq: MPET

Despite the threat of a lawsuit being brought against Magellan Petroleum and its Board of Directors, shares have risen over the past two days. MPET, traded on the Nasdaq, On January 10 the shares began trading around $5, on January 11 the New York firm of Monteverde & Associates PC announced an investigation into Magellan, and MPET ended at $13.20 on January 12.

According to a press release, the investigation focuses on whether Magellan and/or its Board of Directors violated federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by 1) failing to properly value the merger and 2) failing to disclose all material information in connection with the merger. Under the terms of the agreement, Tellurian Investments common stockholders will receive 1.30 shares of Magellan common stock for each share of Tellurian Investments common stock that they hold immediately prior to the effective time of the merger. The merger was valued at $207 million.

Magellan Petroleum has reported negative EPS since 2013 when it reported a loss of $2.83 EPS. In 2016 Magellan reported a narrower loss of $0.17. Magellan Petroleum has no reported sales for 2015 and 2016. Only one firm follows Magellan Petroleum and rates shares of MEPT as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Neuroderm Ltd. (Nasdaq: NDRM) Posting Near Highs Despite Index Drop

NeuroDerm Ltd. – Nasdaq: NDRM

Israeli-based Neuroderm Ltd. was dropped from the Nasdaq Biotechnology Index in December yet shares have rebounded from the subsequent sell-off amidst heavy volumes. The shares, traded on the Nasdaq under ticker NDRM, are last at $23.45 – the highest they have traded since September of 2015.

NeuroDerm is a clinical-stage pharmaceutical company developing treatments for central nervous system disorders designed to make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

Five firms follow Neuroderm Ltd. Four give NDRM a “Strong Buy” rating and one rates NDRM as a “Buy”. Their consensus price target is $30. Neuroderm Ltd. has no reported sales and gas never posted positive EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/12/2017
Ticker Symbol NDRM
Last Price a/o 1:38 PM EST  $                    22.85
Average Volume 151,000
Market Cap $532 million
Sales
Shares Outstanding 25.5 million
Share Float 15.14 million
Shortable Yes
Optionable Yes
Inside Ownership 52.73%
Short Float 4.72%
Short Interest Ratio 4.71
Quarterly Return 14.84%
YTD Return -5.86%
Year Return 45.04%

Century Aluminum (Nasdaq: CENX) Up on WTO Complaint Reports

Century Aluminum Company – Nasdaq: CENX

Reports that the U.S. may launch formal complaints with the World Trade Organization against Chinese aluminum producers sent shares of Century Aluminum (Nasdaq: CENX) up at least 10% in early trading. The U.S. intends, according to reports, to accuse China of providing below-market financing to Chinese aluminum companies that allowed them to modernize their plants and expand production. Also, allegedly in the complaint, are accusations that the Chinese aluminum producers were sold energy, in the form of coal and electricity, at below-market rates.

Chicago, IL-based Century Aluminum Company is a global producer of aluminum and operates aluminum reduction facilities in the United States and Iceland. Century Aluminum owns three U.S. aluminum smelters, in Hawesville, Kentucky, Robards, Kentucky and Mt. Holly, South Carolina, and one smelter in Grundartangi, Iceland. In 2008, Century Aluminum began construction on an aluminum reduction facility in Helguvik, Iceland, construction of which is currently delayed.

Four firms follow Century Aluminum Company and all rate shares of CENX as a “Hold”. CENX is currently trading above its consensus price target of $7.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/12/2017
Ticker Symbol CENX
Last Price a/o 10:13 AM EST  $                    10.01
Average Volume 2 million
Market Cap $809 million
Sales $1.36 Billion
Shares Outstanding 90 million
Share Float 49.3 million
Shortable Yes
Optionable Yes
Inside Ownership 43.00%
Short Float 23.31%
Short Interest Ratio 5.63
Quarterly Return 20.51%
YTD Return 5.02%
Year Return 201.68%

GenVec, Inc. (Nasdaq: GNVC) Posts Big Gains

Genvec, Inc. – Nasdaq: GNVC

Genvec, Inc shares rose over 75% in today’s trading. The shares, traded on the Nasdaq under ticker GNVC, ended yesterday at $4.97. Today they rose to a high of $10.44 before ending the session at $8.79. Volumes for GNVC averaged around 100,000 but today volume reached over 17 million.

GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenovectored product candidates that can deliver on the promise of gene-based medicine. On January 5th, Genvec, Inc. an exclusive option agreement with Washington University in St. Louis, MO to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting.

A single firm follows Genvec and their analyst gives GNVC a rating of “Strong Buy”. Genvec has never experienced positive EPS and last year reported a loss of $3.90 EPS. While Genvec has reported sales each year since 2011, 2015 represented its weakest year – Genvec posted sales of only $900,000 versus $17.7 million in 2011.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/10/2017
Ticker Symbol GNVC
Last Price a/o 4:00 PM EST  $                      8.79
Average Volume 100,000
Market Cap $22.33 million
Sales $600k
Shares Outstanding 2.54 million
Share Float 1.72 million
Shortable Yes
Optionable No
Inside Ownership 1.10%
Short Float 2.25%
Short Interest Ratio 0.39
Quarterly Return 114.39%
YTD Return 173.83%
Year Return 22.08%

Barracuda Networks, Inc. (NYSE: CUDA) Beats Estimates – Rises in After-Hours Market

Barracuda Networks, Inc. – NYSE: CUDA

Barracuda Networks, Inc. beat street earnings estimates and rose over 8% in after-hours trading. Traded on the Nasdaq, CUDA shares rose to an after-hours high of $25.87. Street estimates, on average, were for Barracuda Networks, Inc. to earn $0.15 per share. The Campbell, CA-based company reported $0.22 EPS after posting loss for the same quarter last year. Revenue was also higher than street estimates – $88.8 million vs. $86.9 million.

Barracuda Networks, Inc. offers industry-leading solutions designed to solve mainstream IT problems. Their products span three distinct markets, including: 1) content security, 2) networking and application delivery and 3) data storage, protection and disaster recovery. CitiBank, Coca-Cola, Delta Dental, FedEx, Harvard University, IBM, L’Oreal, Liberty Tax Service, Mythbusters and Spokane Public Schools are among the more than 150,000 organizations in 100+ countries confidently protecting their users, applications and data with Barracuda solutions. Their network has 1000+ employees, 5000+ partners, and offices in 15 countries.

CUDA has reported increasing sales figures every year since 2012 when it reported $160.9 million. In 2016 Barracuda Networks, Inc. reported $320.2 million. Fourteen firms follow CUDA, with eight rating it a “Strong Buy”, one rates it a “Buy”, three rate CUDA as a “Hold”, and two rate it as a “Sell”. Consensus price target amongst analysts is $28.00.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/10/2017
Ticker Symbol CUDA
Last Price a/o 7:59 PM EST  $                    25.70
Average Volume 663,430
Market Cap $1.23 Billion
Sales $338.4 million
Shares Outstanding 51.71 million
Share Float 32.48 million
Shortable Yes
Optionable Yes
Inside Ownership 12.50%
Short Float 2.22%
Short Interest Ratio 1.1
Quarterly Return -0.25%
YTD Return 10.92%
Year Return 121.53%

Enteromedics Inc. (Nasdaq: ETRM)

EnteroMedics Inc.– Nasdaq: ETRM

Enteromedics Inc has had four continuous days of gains. Traded on the Nasdaq under ticker ETRM, the biotech stock had a reverse split in late December. What is newsworthy of late is the massive relative volumes that have been associated with the stock. Below is our original report from January 6, 2017.

____________________________________________

Shares of MN-based EnteroMedics Inc. are up over 80% in pre-market trading on heavy volume. Shares are traded on the Nasdaq under the ticker symbol ETRM. ETRM closed at $2.09 on Wednesday, $3.97 on Thursday, and have traded as high as $7.62.

EnteroMedics® Inc. develops therapies for obesity. It has developed vBloc® vagal blocking therapy, a patented therapeutic approach to treat a range of gastrointestinal and metabolic diseases. vBloc® is a weight loss treatment that addresses the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension.

vBloc® Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, controls both hunger and fullness by blocking the primary nerve which regulates the digestive system. The Maestro Rechargeable System has received Food and Drug Administration (FDA) approval as well as CE Mark in Europe, and has been listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA) for supply in Australia.

Price action seems to be motivated by news that MedStar Health in Maryland and Roper St. Francis in South Carolina, both vBloc institutes, have implanted vBloc Neurometabolic therapies.

EnteroMedics Inc. has no reported sales. Only one firm follows ETRM and rates it as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Genocea Biosciences Inc. (Nasdaq: GNCA) Reports Phase 2b results – shares up

Genocea Biosciences, Inc. – Nasdaq: GNCA

Genocea Biosciences Inc. reported positive results in a Phase 2b clinical trial. Shares (Nasdaq: GNCa) are up over 13% on the news.

Chip Clark, president and chief executive officer of Genocea stated “We are very pleased to have demonstrated such a powerful impact on genital herpes clinical disease in this trial, supporting the groundbreaking potential of GEN-003 to be the first-ever therapeutic vaccine for a chronic infection and the first advance in the treatment of genital herpes in more than 20 years…”

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs.

Five firms follow Gencocea Biosciences Inc. Four rate GNCA as a “Strong Buy” and one rates GNCA a “Buy”. Their consensus pricet target is $15. Genocea Bioscinces reported sales of $700,000 in 2015. This represented a drop from their 2012 reported sales of $2 million. EPS for GNCA have a similar history. Never achieving positive EPS, GNCA had its worst reporting year in 2014 when they lost $2.27 EPS. In 2015 GNCA improved to a loss of $$1,74 EPS.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/5/17
Ticker Symbol GNCA
Last Price a/o 8:50 AM EST $5.15
Average Volume 132,000
Market Cap $130.4 million
Sales 0.50 million
Shares Outstanding 28.74 million
Share Float 24.8 million
Shortable Yes
Optionable Yes
Inside Ownership 0.40%
Short Float 14.15%
Short Interest Ratio 16.56
Quarterly Return 1.79%
YTD Return 10.19%
Year Return -10.63%

Ocular Therapeutix, Inc (Nasdaq: OCUL) Shares up in Pre-Market on Phase 3 Results

OcularTherapeutix, Inc. – Nasdaq: OCUL

Bedford, MA-based Ocular Therapeutix, Inc. shares are up over 8% in pre-market trading. Traded on the Nasdaq under ticker OCUL, the shares are benefitting from positive news that additional positive secondary endpoint results were reached from its most recent successful phase 3 clinical trial of Dextenza™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain.

Dextenza is a product candidate administered by a physician as a bioresorbable intracanalicular insert and designed to release drug to the ocular surface for up to 30 days. Dextenza successfully met the trial’s two primary efficacy endpoints, absence of ocular pain on day 8 and absence of ocular inflammation on day 14 when compared to placebo. In this Phase 3 clinical trial, for which the complete safety assessment will be available in the first quarter of 2017, no treatment-related serious adverse events were observed. Dextenza has exhibited a favorable safety profile and has been well tolerated in all clinical trials, regardless of indication.

“The positive results for the secondary endpoint of absence of ocular flare build upon the successful topline results from this trial which we announced last month,” said Jonathan H. Talamo, M.D., Chief Medical Officer of Ocular Therapeutix.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix plans to resubmit an NDA in the first quarter of 2017 for post-surgical pain for its lead product candidate, Dextenza™.

OCUL shares had an EPS loss of $2.69 in 2014 and a loss of $1.71 in 2015. Sales were $0.8 million in 2014 and $1.8 million in 2015. Four firms follow Ocular Therapeutix, Inc. Two give OCUL shares a “Strong Buy” rating and Two give OCUL a rating of “Buy”. Consensus price tagrte is $26.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/4/17
Ticker Symbol OCUL
Last Price a/o 8:37 AM EST $9.09
Average Volume 1.06 million
Market Cap $206 milion
Sales 1.8 million
Shares Outstanding 24.76 million
Share Float 21.79 million
Shortable Yes
Optionable Yes
Inside Ownership 2.70%
Short Float 23.45%
Short Interest Ratio 4.83
Quarterly Return 21.46%
YTD Return -0.60%
Year Return -6.52%

Titan Pharmaceuticals (Nasdaq: TTNP) Up 15%

Titan Pharmaceuticals Inc. – Nasdaq: TTNP

Titan Pharmaceuticals Inc. trades on the Nasdaq under ticker symbol TTNP. Shares are up almost 15% on heavy volumes. Shares closed on Friday at $4.00 and have reached $4.60 in today’s early trading.

Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. ProNeura implants enhance patient care by providing non-fluctuating, stable levels of medication in the blood for up to one year. Titan is in the early stages of product development programs utilizing ProNeura for the treatment of Parkinson’s disease and hypothyroidism. It’s also evaluating the feasibility of additional product candidates that would be suitable for the treatment of several chronic diseases, including certain hormonal deficiencies; type 2 diabetes, attention deficit hyperactivity disorder, benign prostate hyperplasia and others.

One form covers Titan Pharmaceuticals and gives TTNP a rating of “Strong Buy” with a price target of $11. TTNP reached its highs in EPS ($0.65) and sales ($10.5 million) in 2013. It progressively posted worse figures in 2014 and 2015.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.